12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities

12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, accounting for approximately 25% of all childhood cancer diagnoses and 75% of pediatric leukemias. The disease exhibits a peak incidence between 2 and 5 years of age. ALL originates from the malignant clonal proliferation and arrest of lymphoid progenitor cells within the bone marrow, leading to marrow failure (anemia, thrombocytopenia, neutropenia) and extramedullary blast infiltration into the liver, spleen, lymph nodes, central nervous system (CNS), and testicles.

---

Biology, Immunophenotypes & Risk Stratification

Pediatric ALL is categorized by immunophenotype into B-cell precursor ALL (B-ALL), which accounts for 80% to 85% of cases, and T-cell precursor ALL (T-ALL), which comprises 15% to 20% of cases. T-ALL frequently presents in adolescent males with high-risk clinical features, including prominent mediastinal masses, marked hyperleukocytosis ($WBC > 100,000/\text{mcL}$), early CNS involvement, and high vulnerability to acute tumor lysis syndrome.

National Cancer Institute (NCI) / Rome Risk Criteria

Initial risk stratification governs chemotherapy intensity and is anchored to age and white blood cell (WBC) count at presentation:

• NCI Standard Risk (SR): Age 1.00 to 9.99 years AND initial WBC count $< 50,000/\text{mcL}$ at diagnosis. Associated with an exceptional overall 5-year event-free survival (EFS) exceeding 90%.
• NCI High Risk (HR): Age $< 1.00 year (infant ALL) OR Age $\ge 10.00$ years, OR initial WBC count $\ge 50,000/\text{mcL}$ at diagnosis.

Molecular Cytogenetics & Minimal Residual Disease

• Favorable Prognostic Markers: Hyperdiploidy ($>50$ chromosomes per leukemic cell or DNA index $>1.16$) and the cryptic chromosomal translocation $t(12;21)(p13;q22)$, generating the $ETV6\text{-}RUNX1$ (formerly TEL-AML1) fusion gene. These patients achieve superior cure rates with standard-intensity antimetabolite regimens.
• Unfavorable Prognostic Markers: Hypodiploidy ($<44$ chromosomes), $KMT2A$ ($MLL$) gene rearrangements at 11q23 (such as $t(4;11)$, predominant in infants $<1$ year), intrachromosomal amplification of chromosome 21 (iAMP21), and the Philadelphia chromosome translocation $t(9;22)(q34;q11.2)$, creating the constitutively active $BCR\text{-}ABL1$ tyrosine kinase fusion.
• Ph-Positive ($Ph^+$) ALL Management: Historically associated with a dismal prognosis, children with $Ph^+$ ALL now receive upfront incorporation of an oral BCR-ABL tyrosine kinase inhibitor (TKI):
  • Imatinib: Dosed at 300 to 340 mg/m$^2$/day orally once daily.
  • Dasatinib: Dosed at 60 mg/m$^2$/day orally once daily (demonstrates superior blood-brain barrier penetration and deeper CNS blast clearance).
• Minimal Residual Disease (MRD): The single most powerful independent prognostic indicator in modern pediatric ALL. MRD quantifies submicroscopic leukemic blasts using multi-parameter flow cytometry or next-generation sequencing (NGS). Measured at Day 8/15 (early response) and Day 29 (end of induction). An end-induction bone marrow MRD $< 0.01%$ ($<10^{-4}$ leukemic cells) defines morphological and molecular complete remission. Patients with end-induction MRD $\ge 0.01%$ are intensified to high-risk or very high-risk regimens or directed toward allogeneic hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel).

---

Multi-Agent Chemotherapy Phases

Pediatric ALL protocols (e.g., Children's Oncology Group [COG]) employ a multi-phase backbone spanning 2 to 3 years of total therapy:

1. Induction (4 to 6 Weeks): The primary goal is achieving complete remission ($<5%$ marrow blasts and recovery of normal peripheral blood counts).
   • Standard-Risk (3-Drug Induction): Intravenous vincristine, oral/IV corticosteroid (dexamethasone or prednisone), and intramuscular/IV pegaspargase.
   • High-Risk (4-Drug Induction): Adds an anthracycline (daunorubicin or doxorubicin) to the 3-drug backbone.
   • Intrathecal (IT) chemotherapy is initiated on Day 1 for CNS sanctuary prophylaxis.
2. Consolidation / Intensification (4 to 8 Weeks): Eradicates surviving residual leukemic clones to prevent early relapse. Regimens incorporate cyclophosphamide, cytarabine (Ara-C), oral 6-mercaptopurine (6-MP), and serial intrathecal therapy.
3. Interim Maintenance: Utilizes escalating-dose intravenous methotrexate without leucovorin rescue (Capizzi MTX) or High-Dose Methotrexate (HD-MTX) with leucovorin rescue, paired with vincristine and PEG-asparaginase to maintain systemic control and protect the central nervous system.
4. Delayed Intensification (Re-induction / Re-consolidation): A 6- to 8-week intensification block that "re-challenges" residual leukemic blasts with Induction-like drugs to eliminate resistant clones.
5. Maintenance (2 to 3 Years Total Duration): The longest phase, administered primarily in the outpatient setting to eradicate quiescent blast cells. Standard maintenance consists of:
   • Daily oral 6-mercaptopurine (50–75 mg/m$^2$/day): Administered in the evening on an empty stomach (milk products contain xanthine oxidase, which degrades 6-MP).
   • Weekly oral or IM methotrexate (20 mg/m$^2$/week).
   • Monthly pulses of vincristine (1.5 mg/m$^2$) PLUS dexamethasone (6 mg/m$^2$/day for 5 days).
   • Periodic intrathecal chemotherapy every 12 weeks.

[!IMPORTANT] Pharmacogenomics of 6-Mercaptopurine: 6-MP is metabolized via three competing pathways: xanthine oxidase (inactive 6-thiouric acid), thiopurine S-methyltransferase (TPMT) (inactive 6-methyl-MP), and hypoxanthine-guanine phosphoribosyltransferase (HGPRT) leading to active cytotoxic thioguanine nucleotides (TGNs). Inherited genetic polymorphisms in TPMT and NUDT15 reduce enzymatic inactivation, shunting excessive drug into active TGNs and causing fatal myelosuppression.

• Intermediate Metabolizers (Heterozygotes): Reduce 6-MP starting dose by 30% to 50%.
• Poor Metabolizers (Homozygous variant / compound heterozygotes): Reduce 6-MP starting dose by 80% to 90% (administered 2 to 3 days per week) with close CBC monitoring.

---

High-Risk Antineoplastic Pharmacology & Toxicities

Key High-Risk Chemotherapy Classes in Pediatric ALL:

┌──────────────────────┐     ┌──────────────────────┐     ┌──────────────────────┐
│ High-Dose MTX (HDMTX)│     │     Asparaginase     │     │     Vincristine      │
│ • Crystalluria / AKI │     │ • Pancreatitis       │     │ • Fatal if IT        │
│ • Needs Alkalinizing │     │ • Thrombosis (ATIII) │     │ • Max 2.0 mg Cap     │
│ • Leucovorin Rescue  │     │ • Hypersensitivity   │     │ • Paralytic Ileus    │
└──────────────────────┘     └──────────────────────┘     └──────────────────────┘
            │                            │                            │
            ▼                            ▼                            ▼
┌──────────────────────┐     ┌──────────────────────┐     ┌──────────────────────┐
│     Glucarpidase     │     │    Anthracyclines    │     │ Intrathecal Therapy  │
│ • Emergency Cleavage │     │ • Cardiotoxicity     │     │ • Age-based Dosing   │
│ • Hold Leucovorin ±2h│     │ • Dexrazoxane Chelate│     │ • Preservative-Free  │
└──────────────────────┘     └──────────────────────┘     └──────────────────────┘

1. High-Dose Methotrexate (HD-MTX) & Leucovorin Rescue

High-dose methotrexate (1.0 to 5.0 g/m$^2$ administered as a continuous IV infusion over 24 hours) bypasses active cellular folate transport systems via passive diffusion, achieving high intracellular concentrations that penetrate the blood-brain barrier and testicular tissue.

• Mechanism: Methotrexate competitively inhibits dihydrofolate reductase (DHFR), preventing the conversion of dihydrofolate ($DHF$) to tetrahydrofolate ($THF$). This halts the generation of 5,10-methylene-THF, which is required by thymidylate synthase to convert deoxyuridine monophosphate ($dUMP$) to deoxythymidine monophosphate ($dTMP$). DNA, RNA, and protein synthesis cease, arresting cells in S-phase.
• Elimination & Renal Toxicity: Greater than 90% of an administered MTX dose is excreted unchanged by the kidneys via glomerular filtration and active proximal tubular secretion. Under acidic conditions ($pH < 7.0$), methotrexate and its principal metabolite, 7-hydroxymethotrexate (7-OH-MTX), have extremely low aqueous solubility and precipitate into insoluble yellow crystalline casts within the renal collecting tubules, producing mechanical obstruction, acute tubular necrosis, and acute kidney injury (AKI).
• Prevention Protocol (Hyperhydration & Urine Alkalinization):
  • Hydration: Administer IV fluids containing sodium bicarbonate ($D_5\text{W} + 30\text{--}40\text{ mEq/L NaHCO}_3$) at 125 to 150 mL/m$^2$/hour (2.5 to 3.0 L/m$^2$/day), initiated at least 4 to 6 hours prior to the start of MTX.
  • Alkalinization Target: Urine pH must be $\ge 7.0$ (ideally 7.0 to 8.0) and urine specific gravity must be $\le 1.010$ prior to starting the infusion and maintained until MTX levels clear below $0.1\text{ mcmol/L}$. If urine pH drops below 7.0, administer supplementary IV sodium bicarbonate boluses (1–2 mEq/kg).
  • Drug Interactions to Avoid: Hold interacting medications that compete for renal tubular secretion or displace MTX from albumin: NSAIDs (ketorolac, ibuprofen), penicillins, probenecid, proton pump inhibitors (omeprazole, pantoprazole), and trimethoprim-sulfamethoxazole (TMP-SMX). TMP-SMX is held for 48 to 72 hours surrounding HD-MTX.
• Therapeutic Drug Monitoring & Leucovorin (Folinic Acid) Rescue:
  • Leucovorin Mechanism: 5-formyl-THF enters normal cells via the reduced folate carrier, bypassing DHFR to directly regenerate active intracellular reduced folate pools, rescuing normal bone marrow and mucosal cells from lethal toxicity.
  • Standard Timing: Initiated at hour 36 or 42 from the start of the MTX infusion at a standard dose of 15 mg/m$^2$ IV or PO every 6 hours for 3 to 5 doses.
  • Nomogram-Guided Escalation: Plasma MTX concentrations are drawn at 24, 48, and 72 hours post-infusion start:

$\text{Normal Expected Concentrations:} \quad 24\text{ hours} < 20\text{ mcmol/L}, \quad 48\text{ hours} < 1.0\text{ mcmol/L}, \quad 72\text{ hours} < 0.1\text{ mcmol/L}$

2. Glucarpidase (Voraxaze: Recombinant Carboxypeptidase G2)

Glucarpidase is an FDA-approved rescue enzyme for toxic methotrexate concentrations caused by impaired renal clearance.

• Mechanism: Cleaves the terminal glutamate residue from extracellular methotrexate, converting it into two inactive, non-toxic metabolites: 4-[[2,4-diamino-6-pteridinyl)methyl]amino]benzoic acid (DAMPA) and glutamate. DAMPA is eliminated primarily via the hepatic/biliary route, providing an alternative clearance pathway that lowers plasma MTX by $>95%$ within 15 minutes of administration.
• Indications: Severe MTX-induced acute kidney injury (serum creatinine elevated $\ge 2\times$ baseline) AND a plasma MTX concentration $>2$ standard deviations above the nomogram (e.g., MTX $>50\text{ mcmol/L}$ at 24h, $>5\text{ mcmol/L}$ at 48h, or $>1\text{ mcmol/L}$ at 72h).
• Dosing: 50 units/kg IV as a single bolus injection over 5 minutes.

[!CAUTION] Critical Glucarpidase Drug Interaction & Lab Artifact:

1. Do NOT administer Leucovorin within 2 hours before or 2 hours after Glucarpidase: Leucovorin is a synthetic reduced folate that is structurally similar to methotrexate and serves as an alternative substrate for carboxypeptidase G2. Glucarpidase will rapidly cleave and inactivate leucovorin if co-administered, leaving normal tissues unprotected.
2. Immunoassay Analytical Interference: The inactive metabolite DAMPA cross-reacts with commercial clinical MTX immunoassay antibodies, causing falsely elevated MTX lab reports for 48 hours post-dose. Only high-performance liquid chromatography (HPLC) reliably measures true methotrexate levels during this 48-hour window.

3. Asparaginase Spectrum & Management of Complications

ALL lymphoblasts are deficient in the enzyme asparagine synthetase (ASNS) and cannot synthesize the non-essential amino acid L-asparagine de novo. They depend entirely on circulating plasma asparagine for protein synthesis and cell survival.

• Mechanism: Asparaginase catalyzes the systemic hydrolysis of extracellular L-asparagine into L-aspartic acid and ammonia, starving leukemic lymphoblasts and inducing rapid apoptosis.
• Available Formulations:
  • Pegaspargase (Oncaspar): Escherichia coli-derived asparaginase covalently conjugated to monomethoxypolyethylene glycol (mPEG). Standard dose: 2,500 units/m$^2$ IM or IV every 14 days.
  • Calaspargase pegol-mknl (Asparlas): Possesses a stable succinimidyl carbonate linker providing an extended terminal elimination half-life (16 days vs. 5.5 days for pegaspargase). Dose: 2,100 units/m$^2$ IV every 21 days.
  • Recombinant Erwinia chrysanthemi (Rylaze): Indicated for patients who develop severe clinical hypersensitivity or silent inactivation to pegylated E. coli formulations. Dosing: 25 mg/m$^2$ IM every 48 hours (Monday/Wednesday) and 50 mg/m$^2$ on Friday.
• Signature Complications & Pharmacotherapy:
  • Hypersensitivity & Silent Inactivation: Ranging from mild localized erythema to life-threatening anaphylaxis. IgG neutralizing anti-asparaginase antibodies can also neutralize enzyme activity without triggering allergic symptoms—termed silent inactivation. This results in subtherapeutic asparagine depletion and increased risk of leukemic relapse. Therapeutic drug monitoring via Nadir Serum Asparaginase Activity (NSAA) is performed; if the 14-day nadir NSAA is $< 0.1\text{ IU/mL}$, silent inactivation is diagnosed, and the patient must be switched to Erwinia.
  • Acute Pancreatitis: Occurs in 5% to 10% of children due to profound systemic protein synthesis arrest and pancreatic micro-thrombosis. Characterized by severe epigastric abdominal pain radiating to the back and serum lipase/amylase elevated $>3\times$ upper limit of normal. Permanent discontinuation of all asparaginase formulations is mandatory for Grade 3 or 4 pancreatitis, hemorrhagic pancreatitis, or pancreatic pseudocyst formation.
  • Thrombosis & Coagulopathy: Asparaginase suppresses hepatic synthesis of multiple plasma proteins, producing a biphasic coagulopathy. Most critically, it severely depletes Antithrombin III (ATIII), protein C, and protein S, leading to life-threatening venous thromboembolism (particularly cerebral sagittal sinus thrombosis and deep venous thrombosis). Concurrently, it depletes fibrinogen (hypofibrinogenemia). Management includes:
    • Hold asparaginase during acute thrombosis.
    • Therapeutic anticoagulation with low-molecular-weight heparin (enoxaparin 1 mg/kg subcutaneously every 12 hours) or unfractionated heparin.
    • If ATIII activity is $< 50%\text{--}60%$, administer Antithrombin III concentrates.
    • If fibrinogen falls below $< 100\text{ mg/dL}$ with active bleeding or prior to invasive lumbar punctures, administer cryoprecipitate (1 unit per 5–10 kg).
  • Hepatotoxicity & Hyperglycemia: Transient elevation in transaminases, direct hyperbilirubinemia, and insulin-deficient hyperglycemia (managed with subcutaneous insulin).

4. Vincristine Safety & Intrathecal Route Error Prevention

Vincristine is a Vinca alkaloid that binds to $\beta$-tubulin, preventing microtubule assembly, disrupting mitotic spindles, and arresting dividing cells in metaphase.

• Dosing & Pediatric Cap: Dosed at 1.5 mg/m$^2$ IV, capped at a strict maximum dose of 2.0 mg in pediatric ALL regimens to prevent life-threatening neurotoxicity.
• Dose-Limiting Toxicities: Sensorimotor peripheral neuropathy (loss of deep tendon reflexes, bilateral wrist/foot drop, paresthesias, neuropathic jaw pain) and autonomic neuropathy manifested as severe constipation, adynamic paralytic ileus, and abdominal pain. A scheduled prophylactic bowel regimen (stimulant laxative such as senna plus polyethylene glycol) is mandatory during vincristine therapy.

[!CAUTION] The Vincristine Safety Imperative (Fatal if Given Intrathecally): Accidental intrathecal (IT) injection of vincristine produces 100% fatal ascending myeloradiculopathy, liquefactive spinal cord necrosis, and catastrophic encephalopathy. Patients experience progressive ascending paralysis, intractable central pain, coma, and death within days to weeks.

• ASHP and ISMP National Safety Mandates:
  1. Never dispense vincristine in a syringe.
  2. Vincristine must be diluted exclusively in a small-volume intravenous piggyback mini-bag (25 to 50 mL of $D_5\text{W}$ or 0.9% NaCl) to physically prevent connection to a lumbar puncture needle or spinal catheter.
  3. Bags must carry a prominent fluorescent label: "FOR INTRAVENOUS USE ONLY - FATAL IF GIVEN BY OTHER ROUTES."
  4. Intravenous vincristine and intrathecal chemotherapy should be dispensed, transported, and administered at separate times and through segregated processes.

5. Anthracyclines & Cardioprotection

Doxorubicin and daunorubicin intercalate between DNA base pairs, inhibit topoisomerase II, and generate iron-catalyzed reactive oxygen species (ROS) that induce severe cardiomyocyte membrane peroxidation and mitochondrial vacuolization.

• Toxicity Profile: Chronic, irreversible, dose-dependent dilated cardiomyopathy and congestive heart failure. Children are uniquely susceptible to late-onset cardiotoxicity occurring years to decades after therapy completion, as anthracyclines arrest the normal developmental hypertrophic expansion of pediatric cardiomyocytes.
• Lifetime Cumulative Dose Limits: Anthracyclines are restricted to a lifetime cumulative dose ceiling of 300 to 450 mg/m$^2$ doxorubicin equivalents (or $\le 250\text{ mg/m}^2$ in infants and young children). Serial echocardiography (monitoring left ventricular ejection fraction [LVEF] and fractional shortening [FS]) is performed prior to each cycle.
• Dexrazoxane (Zinecard): An intracellular iron chelator that hydrolyzes inside cardiomyocytes into ADR-925, binding free iron and preventing ROS generation. Administered at a 10:1 dose ratio relative to doxorubicin (e.g., 500 mg/m$^2$ dexrazoxane for 50 mg/m$^2$ doxorubicin) as an IV infusion completed within 30 minutes prior to anthracycline administration.

6. Intrathecal (IT) Chemotherapy for CNS Sanctuary Prophylaxis

Leukemic blasts sequester behind the blood-brain barrier in the arachnoid space, where systemic chemotherapy penetration is inadequate. Universal CNS prophylaxis is mandatory for all pediatric ALL patients.

• Intrathecal Regimens: Single-agent IT Methotrexate OR Triple Intrathecal (TIT) therapy consisting of Methotrexate, Cytarabine (Ara-C), and Hydrocortisone.
• Age-Based Dosing Principle: Because central nervous system volume and cerebrospinal fluid (CSF) volume correlate with brain weight rather than body surface area or body weight—reaching adult volume (~140 mL) by 3 years of age—intrathecal medications are dosed strictly by patient age, not BSA:

[!IMPORTANT] Intrathecal medications must be formulated exclusively with preservative-free diluents. Benzyl alcohol, parabens, and phenol preservatives cause fatal chemical arachnoiditis, demyelination, and paraplegia when introduced into the subarachnoid space.